Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP892485.RAHL9dJVu7bLB-a2BrU6i1NoPkRlXGSzVjvwnxPRN9lKo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP892485.RAHL9dJVu7bLB-a2BrU6i1NoPkRlXGSzVjvwnxPRN9lKo130_assertion type Assertion NP892485.RAHL9dJVu7bLB-a2BrU6i1NoPkRlXGSzVjvwnxPRN9lKo130_head.
- NP892485.RAHL9dJVu7bLB-a2BrU6i1NoPkRlXGSzVjvwnxPRN9lKo130_assertion wasGeneratedBy ECO_0000203 NP892485.RAHL9dJVu7bLB-a2BrU6i1NoPkRlXGSzVjvwnxPRN9lKo130_provenance.
- NP892485.RAHL9dJVu7bLB-a2BrU6i1NoPkRlXGSzVjvwnxPRN9lKo130_assertion wasDerivedFrom befree-20140225 NP892485.RAHL9dJVu7bLB-a2BrU6i1NoPkRlXGSzVjvwnxPRN9lKo130_provenance.
- NP892485.RAHL9dJVu7bLB-a2BrU6i1NoPkRlXGSzVjvwnxPRN9lKo130_assertion SIO_000772 22021366 NP892485.RAHL9dJVu7bLB-a2BrU6i1NoPkRlXGSzVjvwnxPRN9lKo130_provenance.
- NP892485.RAHL9dJVu7bLB-a2BrU6i1NoPkRlXGSzVjvwnxPRN9lKo130_assertion evidence source_evidence_literature NP892485.RAHL9dJVu7bLB-a2BrU6i1NoPkRlXGSzVjvwnxPRN9lKo130_provenance.
- NP892485.RAHL9dJVu7bLB-a2BrU6i1NoPkRlXGSzVjvwnxPRN9lKo130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP892485.RAHL9dJVu7bLB-a2BrU6i1NoPkRlXGSzVjvwnxPRN9lKo130_provenance.